#Boston #Denmark #CathVision #ECGenius #NYU

CathVision Showcases Innovations at the AF Symposium 2025

CathVision, a frontrunner in advanced electrophysiology (EP) solutions, is gearing up for its participation in the AF Symposium, a premier event dedicated to managing cardiac arrhythmias, taking place in Boston this January. Known for its commitment to enhancing EP labs worldwide, the company is eager to showcase its promising advancements and share groundbreaking scientific research.

The ECGenius System and Innovations

At the symposium, attendees will have the opportunity to delve into the cutting-edge features of the ECGenius System, a flagship product designed to provide healthcare professionals with high-quality cardiac signal data along with optimized workflows. This innovative technology enhances the overall electrophysiological procedures, thus promising improved patient outcomes and increased efficiency in clinical settings. Visitors are encouraged to engage with the CathVision team to explore the latest developments, including insights into unipolar signal analysis for pulsed-field ablation and automated measures for conduction system pacing that will be the topic of future clinical trials.

Collaborative Research with NYU

A significant highlight at the event will be the presentation of new research focused on atrial tachycardia entrainment software, developed in collaboration with esteemed researchers Dr. Alexander Kushnir and Dr. Larry Chinitz from New York University (NYU) Langone Health. This study illustrates how CathVision’s technology aids in providing deeper clinical insights, automating key measurements, and displaying data in innovative formats, which ultimately enhances physicians’ decision-making processes when navigating complex ablation cases.

Dr. Kushnir emphasizes the importance of this research, stating, "The goal of a cardiac ablation procedure is to specifically target the arrhythmia circuit. Entrainment mapping is a vital tool that remains underutilized, primarily due to challenges in its implementation and interpretation. Our collaboration with CathVision has led to the creation of state-of-the-art entrainment tools designed to assist physicians in detecting and entraining reentrant arrhythmias and recognizing optimal ablation targets. We are eager to further explore the capabilities of this technology in future research trials."

CathVision's Commitment to Advancing Electrophysiology

With its headquarters in Denmark and an operational office in Minnesota, CathVision is committed to revolutionizing the field of electrophysiology. The company’s innovative ECGenius System and AI-driven platform, CARDIALYTICS, aim to empower medical professionals by delivering precise cardiac electrical signals that facilitate the effective diagnosis, characterization, and treatment of heart rhythm disorders. Founded in 2013, CathVision continues to push the boundaries of medical technology, aiming to improve patient care globally.

For more information regarding their latest updates, including insights into the ECGenius System and CARDIALYTICS, visit CathVision’s website or connect with them on LinkedIn. The AF Symposium promises to be an exciting platform for medical professionals, researchers, and technology innovators to come together and exchange crucial insights that could shape the future of cardiac care.

Conclusion

As CathVision steps onto the stage at the AF Symposium, the anticipation surrounding their innovative solutions and collaborative research highlights a significant advancement in electrophysiologic technology. Their dedication to enhancing clinical outcomes and empowering physicians is set to create a meaningful impact in the management of cardiac arrhythmias, making this event one to watch for all health care professionals involved in cardiology and electrophysiology.